A Prismatic View of the Epigenetic-Metabolic Regulatory Axis in Breast Cancer Therapy Resistance

Authors

Chandrima Das
Apoorva Bhattacharya
Swagata Adhikari
Atanu Mondal
Payel Mondal
Santanu Adhikary
Siddhartha Roy
Kenneth Ramos
Kamlesh K Yadav
John A Tainer
Tej K Pandita

Publication Date

6-1-2024

Journal

Oncogene

Abstract

Epigenetic regulation established during development to maintain patterns of transcriptional expression and silencing for metabolism and other fundamental cell processes can be reprogrammed in cancer, providing a molecular mechanism for persistent alterations in phenotype. Metabolic deregulation and reprogramming are thus an emerging hallmark of cancer with opportunities for molecular classification as a critical preliminary step for precision therapeutic intervention. Yet, acquisition of therapy resistance against most conventional treatment regimens coupled with tumor relapse, continue to pose unsolved problems for precision healthcare, as exemplified in breast cancer where existing data informs both cancer genotype and phenotype. Furthermore, epigenetic reprograming of the metabolic milieu of cancer cells is among the most crucial determinants of therapeutic resistance and cancer relapse. Importantly, subtype-specific epigenetic-metabolic interplay profoundly affects malignant transformation, resistance to chemotherapy, and response to targeted therapies. In this review, we therefore prismatically dissect interconnected epigenetic and metabolic regulatory pathways and then integrate them into an observable cancer metabolism-therapy-resistance axis that may inform clinical intervention. Optimally coupling genome-wide analysis with an understanding of metabolic elements, epigenetic reprogramming, and their integration by metabolic profiling may decode missing molecular mechanisms at the level of individual tumors. The proposed approach of linking metabolic biochemistry back to genotype, epigenetics, and phenotype for specific tumors and their microenvironment may thus enable successful mechanistic targeting of epigenetic modifiers and oncometabolites despite tumor metabolic heterogeneity.

Keywords

Humans, Breast Neoplasms, Epigenesis, Genetic, Drug Resistance, Neoplasm, Female, Gene Expression Regulation, Neoplastic, Metabolic Networks and Pathways

Comments

PMID: 38719949